ClinicalTrials.gg

Program

SSS55

A development code.

Its studies are led by 3SBio.

Furthest: phase 1, since May 26, 20251 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio11 open or runningphase 1since May 26, 2025May 26, 2025Dec 2026phase 1 · NCT07058779

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2025First study: phase 1 study in Safety IssuesFirst studyNCT07058779 · 26 planned · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in Safety IssuesNCT07058779

TargetBeta

C3 →read by rule
“SSS55 is an injection targeting complement C3b”study text, by rule · the study

Other programs on C3

ProgramCompanyFurthest phaseStudies
pegcetacoplanruleBiogenphase 430

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07058779Safety Issues · China1RecruitingDec 202626

How it is read

Names in the registry

  • “SSS55”, 1 entry

Codes read as this program: SSS55.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.